<DOC>
	<DOCNO>NCT00683631</DOCNO>
	<brief_summary>The purpose protocol provide access Therasphere treatment patient liver tumor .</brief_summary>
	<brief_title>TheraSphere HUD For Treatment Unresectable Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description>Surgical resection affect portion liver offer best chance disease-free survival patient primary liver cancer ( hepatocellular carcinoma ( HCC ) ) . Unfortunately , patient present disease amenable surgery ( multifocal disease ) medical contraindication surgery ( limited hepatic reserve relate advanced cirrhosis chronic hepatitis ) . Fewer 15 % HCC patient suitable surgical candidate . The objective treatment TheraSphere selectively administer potentially lethal dose radioactive material cancerous tissue liver patient HCC . This type regional therapy may several advantage systemically administer treatment may also value 'bridging ' treatment HCC patient await donor organ liver transplantation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients 18 year age , race sex , histologic proof primary cancer liver , able give inform consent , eligible . Patients must ECOG Performance Status score great equal 2 , life expectancy &gt; 3 month , nonpregnant acceptable contraception premenopausal woman . The histopathology confirmation criterion may waive patient radiographically identifiable liver mass , know laboratory clinical risk factor cancer elevate tumor marker AFP ( clinical diagnosis ) . Participation TheraSphere Registry . Contraindications angiography selective visceral catheterization Evidence potential delivery great 16.5 mCi ( 30 Gy absorb dose ) radiation lung Evidence detectable Tc99 MAA flow stomach duodenum , application establish angiographic technique stop flow Significant extrahepatic disease represent imminent lifethreatening outcome Severe liver dysfunction pulmonary insufficiency Active uncontrolled infection Pregnancy Refusal participate TheraSphere Registry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>liver cancer</keyword>
	<keyword>liver tumor</keyword>
	<keyword>HCC</keyword>
	<keyword>hepatocellular carcinoma</keyword>
	<keyword>hepatoma</keyword>
</DOC>